ESC guidelines on dual antiplatelet therapy (DAPT). European Society of Cardiology. 2017. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/2017-focused-update-on-dual-antiplatelet-therapy-dapt. Accessed 9 Jun 2021.
Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73:1681–709.
CAS PubMed Article Google Scholar
Faridi KF, Garratt KN, Kennedy KF, et al. Physician and hospital utilization of P2Y12 inhibitors in ST-segment-elevation myocardial infarction in the United States: a study from the National Cardiovascular Data Registry’s Research to practice initiative. Circ Cardiovasc Qual Outcomes. 2020;13:e006275.
Sinnaeve P, Fahrni G, Schelfaut D, et al. Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction. J Am Coll Cardiol. 2020;75:2588–97.
CAS PubMed Article Google Scholar
Milluzzo RP, Franchina GA, Capodanno D, Angiolillo DJ. Selatogrel, a novel P2Y12 inhibitor: a review of the pharmacology and clinical development. Expert Opin Investig Drugs. 2020;29:537–46.
CAS PubMed Article Google Scholar
Mallouk N, Labruyère C, Reny J-L, et al. Prevalence of poor biological response to clopidogrel: a systematic review. Thromb Haemost. 2012;107:494–506.
CAS PubMed Article Google Scholar
Danielak D, Karaźniewicz-Łada M, Komosa A, et al. Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. Eur J Clin Pharmacol. 2017;73:1623–32.
CAS PubMed PubMed Central Article Google Scholar
Biswas M, Kali SK. Association of CYP2C19 Loss-of-function alleles with major adverse cardiovascular events of clopidogrel in stable coronary artery disease patients undergoing percutaneous coronary intervention: meta-analysis. Cardiovasc Drugs Ther. 2021.
Pereira NL, Rihal C, Lennon R, et al. Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv. 2021;14:739–50.
Hou X, Shi J, Sun H. Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. Eur J Clin Pharmacol. 2014;70:1041–7.
CAS PubMed Article Google Scholar
Alakbarzade V, Huang X, Ster IC, McEntagart M, Pereira AC. High on-clopidogrel platelet reactivity in ischaemic stroke or transient ischaemic attack: systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2020;29:104877.
Fontana P, Gaussem P, Aiach M, Fiessinger J-N, Emmerich J, Reny J-L. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation. 2003;108:2971–3.
Fontana P, Dupont A, Gandrille S, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003;108:989–95.
CAS PubMed Article Google Scholar
Kim M-J, Jeong ES, Park J-S, et al. Multiple cytochrome P450 isoforms are involved in the generation of a pharmacologically active thiol metabolite, whereas paraoxonase 1 and carboxylesterase 1 catalyze the formation of a thiol metabolite isomer from ticlopidine. Drug Metab Dispos. 2014;42:141–52.
CAS PubMed Article Google Scholar
Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol. 2010;50:126–42.
CAS PubMed Article Google Scholar
Sangkuhl K, Klein TE, Altman RB. Clopidogrel pathway. Pharmacogenet Genomics. 2010;20:463–5.
CAS PubMed PubMed Central Article Google Scholar
Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007;81:735–41.
CAS PubMed Article Google Scholar
Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92–9.
CAS PubMed Article Google Scholar
Rehmel JLF, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos. 2006;34:600–7.
CAS PubMed Article Google Scholar
Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007;35:1096–104.
CAS PubMed Article Google Scholar
Williams ET, Bacon JA, Bender DM, et al. Characterization of the expression and activity of carboxylesterases 1 and 2 from the beagle dog, cynomolgus monkey, and human. Drug Metab Dispos. 2011;39:2305–13.
CAS PubMed Article Google Scholar
Dean L. Prasugrel therapy and CYP genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kane MS, Kattman BL, et al., editors. Med Genet Summ. Bethesda (MD): National Center for Biotechnology Information (US); 2012. http://www.ncbi.nlm.nih.gov/books/NBK425796/. Accessed 16 Dec 2021.
Li X, Liu C, Zhu X, et al. Evaluation of tolerability, pharmacokinetics and pharmacodynamics of vicagrel, a novel P2Y12 antagonist, in healthy Chinese volunteers. Front Pharmacol. 2018;9:643.
PubMed PubMed Central Article CAS Google Scholar
Zheng Y-D, Zhang H, Zhan Y, et al. Pharmacokinetics, mass balance, and metabolism of [14C]vicagrel, a novel irreversible P2Y12 inhibitor in humans. Acta Pharmacol Sin. 2021;42:1535–46.
CAS PubMed Article Google Scholar
Ufer M, Huynh C, van Lier JJ, Caroff E, Fischer H, Dingemanse J. Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects. Xenobiotica. 2020;50:427–34.
CAS PubMed Article Google Scholar
Beavers CJ, Effoe SA, Dobesh PP. Selatogrel: a novel subcutaneous P2Y12 inhibitor. J Cardiovasc Pharmacol. 2022;79:161–7.
CAS PubMed Article Google Scholar
Haberstock-Debic H, Andre P, Mills S, Phillips DR, Conley PB. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist. J Pharmacol Exp Ther. 2011;339:54–61.
CAS PubMed Article Google Scholar
Angiolillo DJ, Welsh RC, Trenk D, et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012;5:347–56.
CAS PubMed Article Google Scholar
Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038–47.
CAS PubMed Article Google Scholar
BRILINTA (ticagrelor) - Product Monograph. AstraZeneca Canada Inc. 2022. https://www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/brilinta-product-monograph-en.pdf. Accessed 19 Jul 2022.
European Medicines Agency. Kengrexal. 2018. https://www.ema.europa.eu/en/medicines/human/EPAR/kengrexal. Accessed 16 Dec 2021.
Nie X-Y, Li J-L, Zhang Y, et al. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity. J Zhejiang Univ Sci B. 2017;18:37–47.
CAS PubMed PubMed Central Article Google Scholar
Li M-P, Tang J, Wen Z-P, et al. Influence of P2Y12 polymorphisms on platelet activity but not ex-vivo antiplatelet effect of ticagrelor in healthy Chinese male subjects. Blood Coagul Fibrinolysis. 2015;26:874–81.
CAS PubMed Article Google Scholar
Rath CL, Jørgensen NR, Wienecke T. Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke. PLoS One. 2020;15:e0236260.
CAS PubMed PubMed Central Article Google Scholar
Yang H-H, Chen Y, Gao C-Y. Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel. Cardiovasc Ther. 2016;34:460–7.
CAS PubMed Article Google Scholar
Bouman HJ, van Werkum JW, Rudez G, et al. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor. Thromb Haemost. 2010;103:379–86.
CAS PubMed Article Google Scholar
Oestreich JH, Steinhubl SR, Ferraris SP, Loftin CD, Akers WS. Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects. J Thromb Thrombolysis. 2014;38:372–9.
CAS PubMed Article Google Scholar
Kim K-A, Song W-G, Lee H-M, Joo H-J, Park J-Y. Effect of P2Y1 and P2Y12 genetic polymorphisms on the ADP-induced platelet aggregation in a Korean population. Thromb Res. 2013;132:221–6.
CAS PubMed Article Google Scholar
Hassani Idrissi H, Hmimech W, El Khorb N, Akoudad H, Habbal R, Nadifi S. Does i–T744C P2Y12 polymorphism modulate clopidogrel response among Moroccan acute coronary syndromes patients? Genet Res Int. 2017;2017:9532471.
PubMed PubMed Central Google Scholar
Zoheir N, Abd Elhamid S, Abulata N, El Sobky M, Khafagy D, Mostafa A. P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting. Blood Coagul Fibrinolysis. 2013;24:525–31.
CAS PubMed Article Google Scholar
Liu R, Zhou Z-Y, Chen Y-B, et al. Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke. Acta Pharmacol Sin. 2016;37:882–8.
留言 (0)